Current Report Filing (8-k)
June 23 2023 - 3:04PM
Edgar (US Regulatory)
0001626878
false
0001626878
2023-06-23
2023-06-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June
23, 2023
| XBIOTECH
INC. |
| (Exact name of Registrant as specified in its charter) |
| British
Columbia, Canada |
| (State of Incorporation) |
| 001-37347 |
| (Commission File Number) |
| N/A |
| (I.R.S. Employer Identification No.) |
|
5217
Winnebago Ln, Austin,
TX
|
78744
|
| (Address of principal executive offices) |
(Zip Code) |
(512)
386-2900
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule
405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2
of this chapter)
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use
the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a)
of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
The annual meeting of the stockholders of XBiotech Inc. (the “Company”) was held
on June 23, 2023. The matters that were voted upon at the meeting, and the number of votes cast for and against, as well as the number
of abstentions and broker non-votes as to each such matter, are set forth below. Stockholders voted in accordance with the Board of Directors’
recommendations on each matter and voted to (1) elect five nominees for director; (2) ratify the selection by the Audit Committee of the
Board of Directors of Whitley Penn LLP as the Company’s independent registered public accounting firm for the fiscal year ending
December 31, 2023;
Proposal #1 Election of five members of the
Board of Directors
| |
For |
Abstain |
Broker
Non-Votes |
| John
Simard |
8,804,043.00 |
99,883.00 |
2,132,811.00 |
| Jan-Paul
Waldin |
7,206,409.00 |
1,697,517.00 |
2,132,811.00 |
| W.
Thorpe McKenzie |
8,360,436.00 |
543,490.00 |
2,132,811.00 |
| Donald
MacAdam |
8,689,522.00 |
214,404.00 |
2,132,811.00 |
| Peter
Libby |
8,801,167.00 |
102,759.00 |
2,132,811.00 |
Proposal #2 Ratification of the selection
of Whitley Penn LLP as the Company’s independent registered public accounting firm for the fiscal year ending 2023
| For |
Against |
Abstain |
Broker
Non-Votes |
| 10,983,720.00 |
51,402.00 |
1,615.00 |
0 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: June 23, 2023 |
XBIOTECH INC. |
| |
|
|
| |
|
|
| |
By: |
/s/John Simard |
| |
|
John Simard |
| |
|
Chief Executive Officer and President |
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Nov 2024 to Dec 2024
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Dec 2023 to Dec 2024
